MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526898 | Name: KT-362 fumarate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KT-362 is a calcium channel antagonist, potassium channel antagonist and sodium channel antagonist. KT-362 is a new antiarrhythmic agent with vasodilating action on intracellular calcium mobilization of atrial muscle.

Chemical Structure

KT-362 fumarate
KT-362 fumarate
CAS#105394-80-7 ( fumarate)

Theoretical Analysis

MedKoo Cat#: 526898

Name: KT-362 fumarate

CAS#: 105394-80-7 ( fumarate)

Chemical Formula: C26H32N2O7S

Exact Mass:

Molecular Weight: 516.61

Elemental Analysis: C, 60.45; H, 6.24; N, 5.42; O, 21.68; S, 6.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KT-362; KT 362; KT362; KT-362 fumarate.
IUPAC/Chemical Name
1-(3,4-dihydrobenzo[b][1,4]thiazepin-5(2H)-yl)-3-((3,4-dimethoxyphenethyl)amino)propan-1-one fumarate
InChi Key
YIVXAQUBENUHJC-WLHGVMLRSA-N
InChi Code
InChI=1S/C22H28N2O3S.C4H4O4/c1-26-19-9-8-17(16-20(19)27-2)10-12-23-13-11-22(25)24-14-5-15-28-21-7-4-3-6-18(21)24;5-3(6)1-2-4(7)8/h3-4,6-9,16,23H,5,10-15H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
SMILES Code
O=C(N1CCCSC2=CC=CC=C12)CCNCCC3=CC=C(OC)C(OC)=C3.O=C(O)/C=C/C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#105394-80-7 (KT-362 fumarate) CAS# 93392-97-3 (KT-362 Free)

Preparing Stock Solutions

The following data is based on the product molecular weight 516.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ueyama N, Wakabayashi S, Tomiyama T. Change of mechanical activity to contraction from the relaxation induced by the intracellular Ca2+ antagonist KT-362; effects of alkylation of side chain, and substitution of 2,3,4,5-tetrahydro-1,5-benzothiazepine derivatives. Chem Pharm Bull (Tokyo). 1997 Nov;45(11):1761-6. PubMed PMID: 9396151. 2: Tatsukawa Y, Arita M. Effects of KT-362, a sarcolemmal and intracellular calcium antagonist, on calcium transients of cultured neonatal rat ventricular cells: a comparison with gallopamil and ryanodine. Cardiovasc Drugs Ther. 1997 Jan;10(6):667-75. PubMed PMID: 9110109. 3: Erker T. [Studies on the chemistry of thieno-annealed O,N- and S,N-containing heterocyclics. 9. Synthesis and calcium channel blocking action of theino-analogs of KT-362]. Arch Pharm (Weinheim). 1995 Apr;328(4):313-6. German. PubMed PMID: 7611826. 4: Cheng YN, Kiyosue T, Arita M. Effects of KT-362, a new antiarrhythmic agent, on membrane ionic currents of guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1994 Sep;270(3):851-7. PubMed PMID: 7932196. 5: Buljubasic N, Marijic J, Stowe DF, Gross GJ, Kampine JP, Bosnjak ZJ. Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604. PubMed PMID: 1724538. 6: Kodama I, Shibata S. Effects of KT-362, a new antiarrhythmic agent with vasodilating action on intracellular calcium mobilization of atrial muscle. J Pharmacol Exp Ther. 1991 Jul 1;258(1):332-8. PubMed PMID: 2072305. 7: Sakata K, Karaki H. Effects of a novel smooth muscle relaxant, KT-362, on contraction and cytosolic Ca2+ level in the rat aorta. Br J Pharmacol. 1991 Jan;102(1):174-8. PubMed PMID: 1710524; PubMed Central PMCID: PMC1917876. 8: Hester RK, Shibata S. KT-362 related effects on intracellular calcium release and associated clinical potential: arrhythmias, myocardial ischemia, and hypertension. Cardiovasc Drugs Ther. 1990 Oct;4(5):1345-54. Review. PubMed PMID: 2278870. 9: Wakabayashi S, Mochizuki S, Tomiyama A, Shibata S. Effects of KT-362, a new calcium release blocker, on vascular selectivity and hemodynamic actions in anesthetized dogs. Jpn J Pharmacol. 1990 Sep;54(1):23-32. PubMed PMID: 2273645. 10: Pieper GM, Gross GJ. Augmented vascular relaxation to KT-362 in diabetic rat aorta: comparison to diltiazem. J Cardiovasc Pharmacol. 1990 Sep;16(3):394-400. PubMed PMID: 1700209. 11: Hashimoto K, Watanabe K, Mochizuki S, Tomiyama A. Effects of KT-362, a new Na and Ca influx and Ca release inhibitor, on canine ventricular arrhythmias. Jpn J Pharmacol. 1989 Dec;51(4):475-82. PubMed PMID: 2559225. 12: Farber NE, Gross GJ. Collateral blood flow following acute coronary artery occlusion: comparison of a new intracellular calcium antagonist (KT-362) and diltiazem. J Cardiovasc Pharmacol. 1989 Jul;14(1):66-72. PubMed PMID: 2475718. 13: Pelc LR, Farber NE, Warltier DC, Gross GJ. Reduction of myocardial ischemia-reperfusion injury by KT-362, a new intracellular calcium antagonist in anesthetized dogs. J Cardiovasc Pharmacol. 1989 Apr;13(4):586-93. PubMed PMID: 2470996. 14: Eskinder H, Hillard CJ, Wilke RA, Gross GJ. Effect of KT-362, a putative intracellular calcium antagonist, on norepinephrine-induced contractions and inositol monophosphate accumulation in canine femoral artery. J Cardiovasc Pharmacol. 1989 Mar;13(3):502-7. PubMed PMID: 2471898. 15: Farber NE, Gross GJ. Cardioprotective effects of a new vascular intracellular calcium antagonist, KT-362, in the stunned myocardium. J Pharmacol Exp Ther. 1989 Jan;248(1):39-43. PubMed PMID: 2536431. 16: Kodama I, Wakabayashi S, Toyama J, Shibata S, Yamada K. Electrophysiological effects of KT-362, a new antiarrhythmic agent with vasodilating action, on isolated guinea pig ventricular muscle. J Cardiovasc Pharmacol. 1988 Jun;11(6):687-93. PubMed PMID: 2457764. 17: Hartman JC, Al-Wathiqui MH, Brooks HL, Gross GJ, Warltier DC. Hemodynamic and electrocardiographic actions of the new intracellular calcium antagonist, KT-362, in the conscious dog. Pharmacology. 1988;37(6):376-84. PubMed PMID: 3244744. 18: Shibata S, Wakabayashi S, Satake N, Hester RK, Ueda S, Tomiyama A. Mode of vasorelaxing action of 5-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]amino]-1-oxopropyl]-2,3,4,5- tetrahydro-1,5-benzothiazepine fumarate (KT-362), a new intracellular calcium antagonist. J Pharmacol Exp Ther. 1987 Jan;240(1):16-22. PubMed PMID: 3100766.

View History

KAT8 Inhibitor 19

KAT8 Inhibitor 19

Featured